By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted August 10, 2023APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted June 29, 2023APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON AUGUST 10, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted June 14, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) CLEARANCE FOR THE RENUVION MICRO HANDPIECE READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted May 11, 2023APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted May 2, 2023RENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted April 28, 2023APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURING READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted April 5, 2023APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted March 27, 2023RENUVION WINS ADDY AWARD FOR #THISISME CAMPAIGN READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted March 16, 2023APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 27, 2023APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDED READ MORE
